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Early Identiﬁcation of Transthyretin-Related
Hereditary Cardiac Amyloidosis*
Eloisa Arbustini, MD,y Giampaolo Merlini, MDz
Pavia, ItalyAmyloidosis is characterized by the extracellular
deposition of highly-organized ﬁbrillar aggregates
showing a cross-beta super-secondary structure (1).
Several proteins are amyloidogenic in humans, re-
sulting in different clinical presentations, either
systemic or localized. Transthyretin-related he-
reditary amyloidosis (ATTR) is a late-onset,
dominantly inherited systemic amyloidosis. Het-
erozygous gain-of-function mutations in the TTRSee page 502gene confer a high amyloidogenic propensity to
transthyretin (TTR), a plasma protein responsible
for transporting thyroxine and vitamin A and
mostly produced by the liver. Mutations in the TTR
gene destabilize the native tetrameric structure of
TTR, promoting the dissociation into misfolded
monomers, which aggregate and ﬁnally form ﬁbrils
into target tissues. The disease affects the peripheral
and autonomic nerves, leading to severe disability,
cachexia, and death; heart involvement often asso-
ciates with nerve deposition and is responsible for
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Sporadic, senile systemic amyloidosis is a slowly
progressive cardiac amyloidosis that is caused by the
deposition of wild-type TTR, usually affects mainly
male patients older than 60 years of age, and pre-
sents invariably with heart failure.
Diagnosis of ATTR Amyloidosis
The diagnostic workup starts with suspicion of the
disease and takes advantage of clinical expertise,
noninvasive imaging, and biomarkers (3,4). In non-
endemic areas, ATTR amyloidosis remains under-
diagnosed, and the diagnosis is delayed by 3 to 4
years because of the absence of a positive family
history (sporadic cases), varied presentations, and
misdiagnosis (5). In probands, late diagnoses are
common because early phenotypic traits are often
nonspeciﬁc, especially when observed in a frag-
mented clinical fashion. Diagnosis may be expedited
in familial ATTR after the causative mutation of the
disease gene is identiﬁed in the proband. Cascade
family screening identiﬁes early clinical markers
and may provide pre-symptomatic diagnosis.
Transthyretin Amyloid Cardiomyopathy
The diagnostic standards for the diagnosis of amy-
loid cardiomyopathy are those established for light-
chain amyloidosis (AL), recently updated (6), a
mean left ventricular (LV) wall thickness >12 mm,
in the absence of hypertension or other possible
causes of LV hypertrophy, and elevated N-terminal
pro–B-type natriuretic peptide (NT-proBNP) in the
absence of renal failure. With the use of 12 mm as
the cutoff for LV mural thickness, early cardiac
amyloidosis may remain undiagnosed. For instance,
in this issue of iJACC, Kristen et al. (7) describe
endomyocardial biopsy–proven cardiac amyloidosis
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512in a patient with 10-mm LV thickness. In this
patient, scintigraphy showed heart retention of
2.9%, and cardiac magnetic resonance (CMR)
tested negative. Although rare, the endomyocardial
biopsy–veriﬁed amyloid inﬁltration when the
echocardiographic criteria are not fulﬁlled sug-
gests that the heart may be affected far before
being recognized by imaging. However, estab-
lishing the “early cardiac amyloidosis” is a diag-
nostic process that lacks precise criteria. CMR
can either conﬁrm echocardiography-based and/or
biomarker-based diagnosis or add information
about the severity of the inﬁltration. The native or
noncontrast T1 mapping displays a similar diag-
nostic performance and disease tracking for both
cardiac ATTR amyloid and AL amyloid, but
with lower maximal T1 elevation. Native T1
mapping could suggest early cardiac involvement
(8) and is negative in healthy mutation carriers.
Furthermore, technetium-99m-3-3-diphosphono-
1-2-propanodicarboxylic acid (99mTc-DPD) scin-
tigraphy may provide diagnosis earlier than does
CMR-based evaluation (9,10).
Although genetic testing identiﬁes mutated
relatives (potentially including real “early” pa-
tients) of the proband, very few studies have
demonstrated higher yield from family screening.
In the series presented by Rapezzi et al. (10), 15
of 63 (24%) patients with ATTR were identiﬁed
by family screening, and 23 of 63 did not fulﬁll
criteria for “amyloid cardiomyopathy.” However, 7
showed some echocardiographic abnormalities,
but cardiac amyloid was not detected by the
radionuclide imaging. On the other hand, 99mTc-
DPD uptake was seen in 4 of 23 patients without
amyloid cardiomyopathy with normal LV wall
thickness, LV ejection fraction, and transmitral
Doppler proﬁle; E/E0 was abnormal in 1 case, and
1 showed nonspeciﬁc electrocardiographic T-wave
abnormalities (10). These results suggest that
there may be cases in which echocardiography is
more informative than scintigraphy and vice versa.
In a family-based study including 18 mutated
members of 15 families, 6 of 18 patients were
deﬁned as healthy carriers. Scintigraphy in 10 of
12 affected patients with ATTR with normal
baseline echocardiography was performed at each
follow-up occasion together with echocardiogra-
phy and was stopped when the ﬁrst signs of heart
involvement at echocardiography appeared. In 6
patients, abnormal myocardial radiotracer accu-
mulation was detected 1 to 2 years before
morphological echocardiographic abnormalities
were detected (11).Prognostic Stratiﬁcation
In AL amyloidosis, cardiac staging on the basis of
cardiac biomarkers troponin and NT-proBNP (12)
is widely used in clinical trials and patient care;
however, a validated strategy for cardiac workup is
still lacking in ATTR amyloidosis. Kristen et al. (7)
explored the role of multimodality imaging (echo-
cardiography, CMR, and 99mTc-DPD scintigraphy)
and biomarker testing in 60 patients with ATTR
cardiac amyloidosis. Scintigraphic ﬁndings demon-
strated good correlation with echocardiographic
morphologic and functional ﬁndings, cardiac bio-
markers, renal function, and late gadolinium
enhancement. At univariable Cox regression, atrial
ﬁbrillation, NT-proBNP, cardiac troponin T, esti-
mated glomerular ﬁltration rate, mitral annular
plane systolic excursion, LV hypertrophy index, and
heart retention were predictors of outcome; how-
ever, on multivariable analysis, cardiac troponin T
remained the only independent predictor of survival.
Contrary to this result, the study by Rapezzi et al.
(10) reported that the 99mTc-DPD myocardial
uptake is a prognostic determinant of “cardiac”
outcome in ATTR, either alone or in combination
with LV wall thickness. The question is whether the
2 series are comparable. Kristen et al. (7) investi-
gated 70 patients (New York Heart Association
functional class >2: 38.5%), 36 with familial
ATTR and 34 with senile systemic amyloidosis,
with 10 patients not fulﬁlling criteria for cardiac
involvement. Rapezzi et al. (10) studied 63 patients
with genetic ATTR (New York Heart Association
functional class >2: 16%), with 23 patients not
fulﬁlling the criteria for cardiac amyloidosis; 14 of
the latter were identiﬁed by means of family
screening. The prevalence of cases with advanced
cardiac involvement was higher in the former than
in the latter study. Therefore, the results on prog-
nostic stratiﬁcation remain elusive because of the
noncomparable series.
Is it Time for Staging Cardiac Involvement
in ATTR Amyloidosis?
Staging for cardiac involvement in ATTR
amyloidosis could take advantage of family studies
in which at least 3 categories of mutated members
exist: 1) healthy carriers; 2) affected but asymp-
tomatic mutated family members, in whom imag-
ing (CMR, scintigraphy, or echocardiography)
shows abnormal parameters that do not fulﬁll
current criteria for diagnosing cardiac involve-
ment and could be diagnosed with “early cardiac
Figure 1. Diagnostic Process in ATTR Amyloidosis
The availability of effective therapies demands early diagnosis to anticipate severe and frequently irreversible end-organ damage (B, massive
amyloid inﬁltration, in green). Early symptoms are frequently overlooked, and the onset of overt congestive heart failure is associated with
end-stage cardiac damage, refractory to therapy. The combination of genetic testing, high-sensitivity troponins, and cardiac imaging
techniques allows early diagnosis (A, amyloid inﬁltration of a small intramural vessel), widening the diagnostic windows and, consequently,
therapeutic opportunities.
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513amyloidosis;” and 3) patients with overt amyloid
cardiomyopathy, when current echocardiographic
criteria are fulﬁlled. Three simple stages could
provide distinct groups of patients; reverse infor-
mation from genetics to clinics ([geneticþ
/clinics–], [geneticþ/clinics borderline], and
[geneticsþ/clinicsþ]) could group patients into
comparable series, useful for progressing with stage-
speciﬁc diagnostic criteria (Fig. 1). The availability
of new treatment resources for ATTR amyloidosis,
from small molecules such as tafamidis anddiﬂunisal to novel gene-silencing therapies, requires
a staging system for patient stratiﬁcation. Interna-
tional collaboration could gather a wide patient
population to deﬁne and validate a cardiac staging
system.
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